ESMO 2026: Bladder and kidney cancer roundup

ESMO 2026: Prostate cancer roundup

Outpatient administration of xaluritamig for mCRPC: Feasibility and safety

Personalised neoantigen vaccine plus radiotherapy improves progression free survival in advanced solid tumours

Tarlatamab improves long term survival in previously treated small cell lung cancer

Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer

Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer

Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer

ESMO 2026: Surgery in high-risk localised prostate cancer

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer

ESMO 2026: Highlights and analysis